Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5950443 | 0.84 | NOS3 (0.33) | NOS3NOS1NOS2 | |
| SCHEMBL179350 | 0.77 | NOS3 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL22428868 | 0.77 | — | — | |
| SCHEMBL30502967 | 0.77 | NOS3 (0.41) | NOS3NOS1NOS2 | |
| SCHEMBL24966653 | 0.72 | APLNR (0.33) | — | |
| SCHEMBL179362 | 0.72 | NPC1 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL30168086 | 0.72 | NPC1 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL20021704 | 0.72 | — | — | |
| SCHEMBL15481017 | 0.72 | — | — | |
| SCHEMBL179296 | 0.70 | SIRT6 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3689863-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-9487533-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-8993563-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8987280-B2 | Pyrazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8653098-B2 | Pyrazolopyridine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8563540-B2 | Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8445487-B2 | Purine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | US | disclosed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7888352-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIRAMED LIMITED (GB) | 2011-02-15 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225557-A1 | PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | NOS3 2582/4885NOS1 3015/4885NOS2 3115/4885 |
| US-20110112085-A1 | THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | NOS3 3529/4885NOS1 3883/4885NOS2 3965/4885 |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | NOS3 2723/4885NOS1 2543/4885NOS2 3335/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | NOS3 2400/4885NOS1 3265/4885NOS2 3828/4885 |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | NOS3 1740/4885NOS1 3827/4885NOS2 3760/4885 |
| US-20080269210-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | NOS3 1740/4885NOS1 3827/4885NOS2 3760/4885 |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | PI4KA, DMPK, PDPK1 | NOS3 2307/4885NOS1 3577/4885NOS2 3355/4885 |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | NOS3 1740/4885NOS1 3827/4885NOS2 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.